Table 2.
Targeted therapies in oncogene-addicted cancers
| Name | Target | Disease | FDA first approval |
|---|---|---|---|
| Imatinib mesylate (Gleevec®) | BCR-ABL, KITmut, PDGFRmut | CML, GIST | 2001 2002 |
| Trastuzumab (Herceptin®) | HER2ampl | Breast cancer | 1998 |
| Erlotinib (Tarceva®) | EGFRmut | NSCLC | 2004 |
| Gefitinib (Iressa®) | EGFRmut | NSCLC | 2003 |
| Vemurafenib (PLX4032) | BRAFmut | Melanoma | Phase 3 |
| Crizotinib (PF002341066) | ALKtransl | NSCLC | Phase 3 |
| Iniparib (BSI201) | PARP-1 | BRCA-associated (hereditary) or ‘BRCAness’-associated (sporadic) breast and ovarian cancer | Phase 2 |
| Olaparib (AZD2281) | PARP-1 | BRCA-associated (hereditary) or ‘BRCAness’-associated (sporadic) breast and ovarian cancer | Phase 2/3 |
mut, mutant; ampl, amplified; transl, translocated; CML, chronic myeloid leukaemia; GIST, gastro-intestinal stromal tumour; NSCLC, non-small cell lung cancer.